These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 9673855

  • 1. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH, Myllylä V.
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [Abstract] [Full Text] [Related]

  • 2. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ.
    BMJ; 1995 Dec 16; 311(7020):1602-7. PubMed ID: 8555803
    [Abstract] [Full Text] [Related]

  • 3. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug 16; 11(60):108-11. PubMed ID: 12199263
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M.
    Br J Clin Pharmacol; 2018 Sep 16; 84(9):1917-1927. PubMed ID: 29847694
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 16; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ, Fernandez HH.
    Drugs Aging; 2007 Jul 16; 24(8):663-80. PubMed ID: 17702535
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK.
    Neurology; 1998 Sep 16; 51(3):825-30. PubMed ID: 9748034
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A review of the pharmacology of selegiline.
    Heinonen EH, Lammintausta R.
    Acta Neurol Scand Suppl; 1991 Sep 16; 136():44-59. PubMed ID: 1686954
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.